{"id":4973,"date":"2019-05-07T13:05:07","date_gmt":"2019-05-07T07:35:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4973"},"modified":"2021-07-24T12:57:19","modified_gmt":"2021-07-24T07:27:19","slug":"notizia-rg6042","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5eeababe84\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5eeababe84\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042\/#Roches_takes_a_step-_forward_to_treat_Huntingtons_disease\" >Roche&#8217;s takes a step- forward to treat Huntington&#8217;s disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042\/#Pfizers_Tafamidis_back_in_the_Market\" >Pfizer&#8217;s Tafamidis back in the Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042\/#Syapse_Amgen_announces_a_precision_medicine_collaboration_in_oncology\" >Syapse, Amgen announces\na precision medicine collaboration in oncology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042\/#New_approval_for_a_rare_disease_drug_Ruzurgi\" >New approval for a\nrare disease drug Ruzurgi<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roches_takes_a_step-_forward_to_treat_Huntingtons_disease\"><\/span><strong>Roche&#8217;s takes a step- forward to treat Huntington&#8217;s disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>A new drug co-developed by <strong>Roche<\/strong> and <strong>Ionis Pharmaceuticals<\/strong> can be a potential candidate to treat <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">Huntington&#8217;s disease<\/a><\/strong>. <strong>RG6042<\/strong> which is an antisense oligonucleotide is able to successfully lower down the production of a toxic protein that results in dysfunction of neurons. The successful Phase 1\/2a trials have boosted the hopes of Roche to take the drug directly in Phase III trials. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pfizers_Tafamidis_back_in_the_Market\"><\/span><strong>Pfizer&#8217;s Tafamidis back in the Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Once rejected by the U.S. FDA, Pfizer&#8217;s <strong>tafamidis<\/strong> recently was able to win the FDA nod to treat <strong>transthyretin amyloid cardiomyopathy<\/strong>, a rare and fatal heart disease. The oral drug will be sold under the brand name <strong>Vyndaqel <\/strong>is set to bear a price tag worth<strong> USD 225,000. <\/strong>The dug has been set a price which is much lower than that of <strong>Tegsedi <\/strong>a collaborated product of Akcea Therapeutics and Ionis Pharmaceutical and <strong>Onpattro <\/strong>of Alnylam Pharmaceutical.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syapse_Amgen_announces_a_precision_medicine_collaboration_in_oncology\"><\/span><strong>Syapse, Amgen announces\na precision medicine collaboration in oncology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Syapse<\/strong>, a precision medicine software developer has announced to collaborate with <strong>Amgen <\/strong>to advance in <a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\">cancer <\/a>drug development. With the help of Syapse&#8217;s health network, Amgen aims to identify the patients suitable for clinical trials and select the potential drug candidates. Both the companies have decided to work towards the developing of real-world evidence standards to support the acceleration of therapies to market.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"New_approval_for_a_rare_disease_drug_Ruzurgi\"><\/span><strong>New approval for a\nrare disease drug Ruzurgi<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Jacobus Pharmaceutical<\/strong> recently was able to win FDA&#8217;s approval for its drug <strong>Ruzurgi <\/strong>for the treatment of a rare autoimmune disorder <strong>Lambert-Eaton myasthenic syndrome<\/strong> (LEMS) in patients 6 to less than 17 years of age<strong>. <\/strong>The drug is the first ever approved treatment, especially for pediatric patients. Ruzurgi received an ORPHAN designation along with Priority review and Fast Track designations. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche&#8217;s takes a step- forward to treat Huntington&#8217;s disease A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington&#8217;s disease. RG6042 which is an antisense oligonucleotide is able to successfully lower down the production of a toxic protein that results in dysfunction of neurons. The successful Phase 1\/2a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[831,304,305,3815,460,524,3814,3816,1481,593],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-4973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amgen","tag-huntingtons-disease-hd","tag-huntingtons-disease","tag-jacobus-pharmaceuticals","tag-pfizer","tag-roche","tag-ruzuurgi","tag-syapse","tag-tafamidis-meglumine","tag-us-food-and-drug-administration-fda","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 07\/05\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington&#039;s disease. RG6042 which is an...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 07\/05\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington&#039;s disease. RG6042 which is an...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-07T07:35:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09023435\/7-may.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 07\/05\/2019 - DelveInsight Business Research","description":"A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington's disease. RG6042 which is an...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042","og_locale":"en_US","og_type":"article","og_title":"Notizia 07\/05\/2019 - DelveInsight Business Research","og_description":"A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington's disease. RG6042 which is an...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-07T07:35:07+00:00","article_modified_time":"2021-07-24T07:27:19+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09023435\/7-may.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042","url":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042","name":"Notizia 07\/05\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09023435\/7-may.png","datePublished":"2019-05-07T07:35:07+00:00","dateModified":"2021-07-24T07:27:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington's disease. RG6042 which is an...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-rg6042"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-rg6042#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09023435\/7-may.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09023435\/7-may.png","width":647,"height":345,"caption":"Notizia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09023435\/7-may-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Huntington&#039;s disease (HD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">jacobus pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ruzuurgi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Syapse<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tafamidis meglumine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Huntington&#039;s disease (HD)<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">jacobus pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Ruzuurgi<\/span>","<span class=\"advgb-post-tax-term\">Syapse<\/span>","<span class=\"advgb-post-tax-term\">tafamidis meglumine<\/span>","<span class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 7, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 7, 2019 1:05 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Notizia","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4973"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4973\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4974"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4973"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4973"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}